Proactive Investors - Run By Investors For Investors

Inhibikase Therapeutics receives clinical clearance from FDA on its Parkinson's disease therapy

Inhibikase Therapeutics Inc President & CEO Milton Werner sat down with Proactive Investors at the ThinkEquity Conference in New York. The Atlanta-based, privately-held pharma company is focused on developing and commercializing small-molecule kinase inhibitor therapeutics for the treatment of neurological infections and neurodegenerative diseases.

 
Meet Faron Pharmaceuticals Ltd, Belvoir Lettings, Silence Therapeutics PLC, ANGLE PLC and ReNeuron Group PLC at our event, London , 23 May 2019. Register here »
View full IKT profile View Profile

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use